These agents may help prevent strokes in patients with T2D and established ASCVD.111–113 The SGLT2 inhibitors empagliflozin and canagliflozin have less robust data for MACE prevention but may still be considered to reduce risk of MI and CAD.116–120 Both GLP1-RAs and SGLT2 inhibitors may also be considered in patients with T2D and PAD to reduce the risks of cardiovascular events. The gene discussed is SLC5A2; the disease is peripheral arterial disease.